In order to determine if the N-methyl-D-aspartate antagonist ketamine would
reproduce eye movement dysfunction in schizophrenia, we studied 12 normal
control subjects with low dose (0.1 mg/kg) bolus injection of ketamine in a
double-blind placebo-controlled study. Oculomotor measures were obtained d
uring smooth pursuit that included closed loop gain and measures of gain du
ring masking conditions. Measures during initiation of smooth pursuit inclu
ded latency open loop acceleration and velocity. Ketamine disrupted closed
loop gain and open loop acceleration but not measures during the masking co
nditions. The ketamine partly reproduced some abnormalities seen in schizop
hrenia but not measures that may be more specifically linked to familial ab
normalities found in family members of subjects with schizophrenia. (C) 200
0 American College of Neuropsychopharmacology. Published by Elsevier Scienc
e Inc.